ClinicalTrials.gg
CompletedNCT02183116Updated Jul 8, 2014

A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee

A Phase 4 interventional study of Meloxicam in Osteoarthritis, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 34 Years to 74 Years. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
34 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Osteoarthritis by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Boehringer Ingelheim.

Started
1998
with 3 others
Phase 4
3 of 15
none open now
Registered
8th of 15
by date

Among the 15 studies in Osteoarthritis by Boehringer Ingelheim, this one is one of 4 that started in 1998, is one of 3 in phase 4, and was the 8th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 15 studies in Osteoarthritis by Boehringer Ingelheim is open now. The open studies under Osteoarthritis, anywhere →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 34 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Osteoarthritis by Boehringer Ingelheim as a file.
02

Study summary

To Access the Efficacy and Safety of Meloxicam 7.5mg once daily over a treatment period of 56 days

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
34 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Osteoarthritis of the knee requiring the therapy with non-steroidal anti-inflammatory drugs (NSAIDs)

Exclusion criteria

Exclusion Criteria:

none

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Meloxicam

    Drug: Meloxicam

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in pain on active movement assessed by a 100 mm visual analogue scale (100 mm, VAS)

    Time frame: Baseline, 8 weeks after first drug administration

Secondary outcomes

  1. Change from baseline in Lequesne index

    Time frame: Baseline, 8 weeks after first drug administration

  2. Change from baseline in physical examination (tenderness)

    Time frame: Baseline, 8 weeks after first drug administration

  3. Assessment of significant change from baseline in status according endoscopy

    Time frame: Baseline, 8 weeks after first drug administration

  4. Assessment of significant change from baseline in gastrointestinal (GI) symptoms score

    Time frame: Baseline, 8 weeks after first drug administration

  5. Assessment of significant change from baseline in laboratory values

    Time frame: Baseline, 8 weeks after first drug administration

  6. Number of Patients with Adverse Events

    Time frame: Up to 8 weeks after first drug administration

  7. Assessment of significant change from baseline in physical examination (swelling)

    Time frame: Baseline, 8 weeks after treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 1998 and a primary completion of Feb 1999. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
Start
Oct 1998
Primary completionActual
Feb 1999
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183116
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Oct 1998
Primary completion
Feb 1999
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion